Want to take quizzes and track your credits?
A 33-year-old woman with a history of hereditary bilateral retinoblastoma as an infant presented to a primary care clinic with 1 week of right lower extremity swelling. At age 8 months, she was treated with right enucleation and left eye radiotherapy (50.4 Gy). At age 4 years, she developed a recurrence of the retinoblastoma in the nasal cavity and was treated with 4 cycles of vincristine, doxorubicin, and cyclophosphamide followed by 1 cycle of cisplatin, etoposide, and intrathecal cytarabine.
Please finish quiz first before checking answer.
Read the answer below and download your certificate.
Read the discussion below and retake the quiz.
The patient underwent a transvenous biopsy with an inferior vena cava filter, and pathology results were consistent with a leiomyosarcoma (LMS), grade 3. Computed tomography results of the chest, abdomen, and pelvis were negative for metastatic disease. She subsequently underwent a radical resection of the pelvic mass, which revealed a 4-cm mass deriving from and encapsulating the right external iliac vein with R1 margins, which was replaced with an interposition graft.
Retinoblastoma is the most common pediatric ocular tumor. The hereditary variant, which is caused by germline variations to the tumor suppressor gene RB1, comprises 40% of all retinoblastoma and is generally associated with bilateral disease.1 Long-term survival of these patients is typically excellent; however, there remains a 33.1% risk of developing a secondary cancer.2,3 This has important implications for monitoring survivors of hereditary retinoblastoma. The median time to development of a subsequent cancer is 18.9 years, and bone and soft-tissue sarcomas comprise most (40%-60%) subsequent cancers, followed by melanoma, accounting for approximately 10%.3 Among soft-tissue sarcomas (STS), LMS is most common, comprising at least 40% of all STS diagnosed in patients with retinoblastoma with a median age at presentation of approximately 32 years.3 Other commonly diagnosed subsequent STS include fibrosarcoma, undifferentiated pleomorphic sarcoma, and rhabdomyosarcoma.3 Prior treatment with radiation or chemotherapy may increase the risk of a subsequent cancer.4 Radiotherapy is a risk factor for developing a subsequent cancer within the treatment field, and alkylating agents, in particular, seem to increase systemic risk of subsequent cancer. Patients who were treated with radiotherapy and an alkylating agent before age 1 year, as with this patient, may have up to 3.8 times greater risk of developing LMS.4
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Jason Lambden, MSPH, MD, Department of Internal Medicine, McGaw Medical Center of Northwestern University, 251 E Huron St, Chicago, IL 60611 (email@example.com).
Published Online: September 2, 2021. doi:10.1001/jamaoncol.2021.3811
Conflict of Interest Disclosures: None reported.
Additional Contributions: We thank the patient for granting permission to publish this information and Seth Pollack, MD, Northwestern Medicine, for his contributions, for which he was not compensated.
You currently have no searches saved.